How Does Seretide Work in the Body
Chemical Composition, Mechanism of Action & Metabolic Effects Explained
Key Takeaways: How Seretide Works
- Active Ingredients: Salmeterol (long‑acting beta2‑agonist) and fluticasone propionate (inhaled corticosteroid).
- Primary Actions: Salmeterol relaxes airway smooth muscle for 12‑hour bronchodilation; fluticasone reduces inflammation and swelling in the lungs.
- Onset & Duration: Salmeterol begins working within 30–60 minutes; full anti‑inflammatory effect from fluticasone develops over days to weeks. Both components last approximately 12 hours.
- Metabolism: Both drugs are extensively metabolised in the liver, mainly by CYP3A4, to inactive metabolites. Excretion is via faeces and urine.
- Usage: Seretide is a maintenance therapy for asthma (adults and children ≥4 years) and COPD (severe stages), taken twice daily. It is not a reliever for acute attacks.
Seretide combines a long‑acting bronchodilator and a corticosteroid to provide dual control of airway narrowing and inflammation. This synergistic approach helps prevent symptoms and reduce exacerbations in asthma and COPD.
Important Medical Advice
Seretide is not for relief of sudden asthma attacks – always carry a separate fast‑acting reliever inhaler (e.g., salbutamol). Seek immediate medical help if you experience chest tightness, wheezing worsening, or signs of allergic reaction (swelling of face, lips, tongue, or rash) after use.
Chemical Composition & Molecular Structure
Seretide Accuhaler delivers a fixed‑dose combination of two active substances: salmeterol (as salmeterol xinafoate) and fluticasone propionate. Each inhalation provides 50 micrograms of salmeterol and either 100, 250, or 500 micrograms of fluticasone, depending on the strength. The only excipient is lactose monohydrate (which contains trace milk proteins).
Structural Details
4‑hydroxy‑α¹‑[[[6‑(4‑phenylbutoxy)hexyl]amino]methyl]‑1,3‑benzenedimethanol 1‑hydroxy‑2‑naphthoate
A long‑acting beta2‑agonist with a lipophilic side chain that anchors it near the beta2‑receptor, enabling prolonged duration of action. The xinafoate salt improves stability.
S‑(fluoromethyl)‑6α,9‑difluoro‑11β‑hydroxy‑16α‑methyl‑3‑oxo‑17α‑propionyloxyandrosta‑1,4‑diene‑17β‑carbothioate
A synthetic trifluorinated glucocorticoid with high lipophilicity and strong affinity for the glucocorticoid receptor. The propionate ester enhances topical potency and first‑pass metabolism.
Key Pharmaceutical Properties
| Property | Salmeterol | Fluticasone propionate |
|---|---|---|
| Lipophilicity (logP) | 3.1 | 3.6 |
| Protein binding | 96% | 91% |
| Oral bioavailability | <5% (extensive first‑pass) | <1% (extensive first‑pass) |
| Receptor affinity | High beta2‑adrenoceptor (partial agonist) | High glucocorticoid receptor agonist |
🗒️ Pharmaceutical insight: The lactose carrier ensures accurate dose delivery; the Accuhaler device emits the powder with low oropharyngeal deposition, optimising lung targeting.
Mechanism of Action: Dual Seretide Pathway
Seretide’s efficacy stems from complementary actions on two key aspects of obstructive airway diseases.
- Salmeterol (LABA): Salmeterol selectively stimulates beta2‑adrenoceptors on airway smooth muscle. This activates adenylate cyclase, increasing intracellular cAMP and leading to protein kinase A activation, which relaxes muscle fibres. Its long lipophilic side chain allows repeated receptor binding, providing bronchodilation for 12 hours.
- Fluticasone propionate (corticosteroid): After inhalation, fluticasone diffuses into airway epithelial and inflammatory cells, binding to cytoplasmic glucocorticoid receptors. The complex migrates to the nucleus, where it suppresses pro‑inflammatory gene transcription (e.g., cytokines, chemokines) and activates anti‑inflammatory genes (e.g., lipocortin). This reduces eosinophil infiltration, mucus secretion, and vascular permeability.
| Feature | Salmeterol | Fluticasone |
|---|---|---|
| Onset of action | 30–60 minutes | Hours to days (genomic) |
| Peak effect | 2–4 hours | 1–2 weeks |
| Duration | 12 hours | 24 hours (receptor occupancy) |
🗒️ Physiological insight: The prolonged occupancy of salmeterol at beta2‑receptors provides sustained bronchodilation, while fluticasone’s high lipophilicity ensures prolonged airway tissue retention.
Absorption & Distribution (Pharmacokinetics)
Following inhalation from the Accuhaler, approximately 15–30% of the delivered dose reaches the lower respiratory tract; the remainder is deposited in the oropharynx and swallowed.
Pulmonary absorption
Salmeterol is absorbed rapidly from the lungs, reaching peak plasma concentrations within 5–15 minutes, though systemic levels are very low due to high local retention. Fluticasone is absorbed more slowly, with peak plasma at 1–2 hours post‑inhalation.
Distribution
Fluticasone has a very large volume of distribution (~300 L) due to high lipophilicity. Salmeterol also distributes widely (Vd ~120 L). Both are highly protein‑bound (96% and 91% respectively).
Metabolic Effects & Elimination
Fluticasone propionate: Undergoes extensive first‑pass metabolism in the liver via CYP3A4 to an inactive 17β‑carboxylic acid metabolite. Less than 5% of a swallowed dose reaches systemic circulation. Metabolites are excreted primarily in faeces (≥95%) and urine (<5%).
Salmeterol: Metabolised mainly by hydroxylation (CYP3A4) to alpha‑hydroxysalmeterol, which is inactive. The drug and metabolites are excreted approximately 60% in faeces and 25% in urine over 7 days.
⚠️ Metabolic caution: Potent CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) may increase systemic exposure to fluticasone and salmeterol, raising the risk of systemic corticosteroid effects and cardiovascular side effects. Avoid concomitant use unless closely monitored.
Clinical Efficacy in Asthma and COPD
Seretide is licensed for regular maintenance treatment of asthma in adults, adolescents, and children aged 4 years and older, and for symptomatic treatment of severe COPD (FEV₁ <50% predicted) with repeated exacerbations.
- Asthma: In clinical trials, Seretide significantly improves FEV₁, reduces daytime and night‑time symptoms, and decreases the need for rescue medication. The combination allows lower inhaled corticosteroid doses in some patients (steroid‑sparing effect).
- COPD (50/500 strength only): Seretide reduces the frequency of moderate to severe exacerbations and improves lung function and health status. It does not improve survival but reduces symptoms and flare‑ups.
In the TORCH study, Seretide 50/500 reduced the annual rate of COPD exacerbations by 25% compared with placebo.
Seretide FAQs
How long does it take for Seretide to start working?
Salmeterol begins to relax airways within 30–60 minutes, providing sustained bronchodilation. Fluticasone’s anti‑inflammatory effect builds over days, with full benefit seen after 1–2 weeks of regular use.
Can Seretide be used as a reliever inhaler for sudden attacks?
No, Seretide is a maintenance inhaler taken twice daily to prevent symptoms. It should not be used to relieve sudden asthma attacks – always keep a fast‑acting reliever (e.g., salbutamol) with you.
What are the most common side effects of Seretide?
Common side effects include headache, throat irritation, hoarseness, oral thrush (candidiasis), and muscle aches. Rinsing your mouth after use helps prevent thrush.
Is Seretide safe for children?
Yes, Seretide Accuhaler is licensed for children aged 4 years and older with asthma. The lowest strength (50/100) is used twice daily. Regular growth monitoring is recommended.
Can I use Seretide during pregnancy or breastfeeding?
Use only if clearly needed and prescribed by your doctor. Poorly controlled asthma poses greater risks to mother and baby. Discuss the benefits and risks with your healthcare provider.
Need Seretide with Expert Guidance?
If you have asthma or COPD and think Seretide may be appropriate, a UK‑registered doctor can assess your symptoms and provide a prescription online.
Secure Prescription & Next-Day Delivery
MHRA‑compliant | GPhC‑registered pharmacy | Discreet packaging | UK‑registered doctors
Start Asthma ConsultationRelated Seretide Guides
Clinical References & Sources
Medical Content Manager
Nabeel is a co-founder, and medical content manager of Chemist Doctor. He works closely with our medical team to ensure the information is accurate and up-to-date.
Medical Doctor
Dr. Feroz is a GMC-registered doctor and a medical reviewer at Chemist Doctor. He oversees acute condition and urgent care guidance.
Medical Director
Usman is a co-founder, and medical director of Chemist Doctor. He leads the organisation's strategic vision, bridging clinical and operational priorities.
Review Date: 05 March 2026
Next Review: 05 September 2026
Published on: 05 March 2026
Last Updated: 05 March 2026